Understanding concentrated insulins: a systematic review of randomized controlled trials

References

• Bliss M. The Discovery of Insulin. Chicago: The University of Chicago Press, 1982
   Google Scholar
• Sneader W. Drug discovery: A history. Chichester, England: John Wiley and Sons Ltd, 2005
   Google Scholar
• Meneghini L. New insulin preparations: a primer for the clinician. Cleve Clin J Med 2016;83(5Suppl1):S27-S33
   Web of Science ®Google Scholar
• Moss JM, Galloway JA. U-100 insulin. A progress report. JAMA 1977;238:1823-4
   PubMed Web of Science ®Google Scholar
• Owens DR. Human insulin: clinical pharmacological studies in normal man. Lancaster, Boston: MTP Press, 1986
   Google Scholar
• Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-9
   PubMed Web of Science ®Google Scholar
• Segal AR, El Sayed N. Are you ready for more insulin concentrations? J Diabetes Sci Technol 2015;9:331-8
   PubMedGoogle Scholar
• Barnosky A, Shah L, Meah F, et al. A primer on concentrated insulins: what an internist should know. Postgrad Med 2016; 128:381-90
   PubMed Web of Science ®Google Scholar
• Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag 2016;12:389-400
   PubMed Web of Science ®Google Scholar
• Painter NA, Sisson E. An overview of concentrated insulin products. Diabetes Spectr 2016;29:136-40
   PubMedGoogle Scholar
• Segal AR, Vootla T, Beaser RS. Insulin: making sense of current options. Endocrinol Metab Clin North Am 2016;45:845-74
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care 2017;40(Suppl1):S1-S135
   Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract 2017;23:207-38
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W264
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. March 2012. AHRQ Publication No. 12-EHC047-EF. Available at: www.effectivehealthcare.ahrq.gov/ [Last accessed 15 August 2016]
   Google Scholar
• de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 2011;34:2496-501. Erratum in: Diabetes Care 2014;37:2414
   PubMed Web of Science ®Google Scholar
• Hövelmann U, Heise T, Nosek L, et al. Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect. Diabetologia 2012;55(Suppl1):S374-S5, 912U
   Google Scholar
• Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33:515-21
   PubMed Web of Science ®Google Scholar
• Morrow L, Canney L, Pichotta P, et al. Concentrated insulin BIOD-531 is associated with accelerated onset of action compared to Humulin R U-500 and Humalog Mix75/25 and a basal duration profile. Diabetologia 2014;57(Suppl1):S383, 82-LB
   Google Scholar
• Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/mL has the same metabolism as insulin glargine 100 U/mL. Diabetes Obes Metab 2014;16:873-6
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 units•mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units•mL−1. Diabetes Care 2015;38:637-43
   PubMed Web of Science ®Google Scholar
• Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab 2015;17:261-7
   PubMed Web of Science ®Google Scholar
• Jinnouchi H, Koyama M, Amano A, et al. Continuous glucose monitoring during basal–bolus therapy using insulin glargine 300 U mL−1 and glargine 100 U mL−1 in Japanese people with type 1 diabetes mellitus: a crossover pilot study. Diabetes Ther 2015;6:143-52
   PubMed Web of Science ®Google Scholar
• Morrow L, Canney L, Pichotta P, et al. BIOD-531 demonstrates superior prandial glucose control, post-meal dosing flexibility, and less insulin “stacking” compared to marketed prandial/basal insulins. Diabetologia 2015;58(Suppl1):S3, 6
   Web of Science ®Google Scholar
• Morrow L, Han-Conrad L, Canney L, et al. Postmeal glycemia following U-400 ultra-rapid-acting/basal insulin BIOD-531 vs. premixed and U-500 insulins in patients with type 2 diabetes. Diabetes 2015;64(Suppl1):A247-8, 977-P
   Web of Science ®Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/mL provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254-60
   PubMed Web of Science ®Google Scholar
• de la Peña A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog) 100 U/mL. Clin Pharmacol Drug Dev 2016;5:69-75
   PubMed Web of Science ®Google Scholar
• A study of 2 different formulations of insulin lispro in healthy participants. ClinicalTrials.gov. NCT 02111083. Available at: https://clinicaltrials.gov/ct2/show/NCT02111083?term=NCT02111083&rank=1 [Last accessed 30 September 2016]
   Google Scholar
• Bergenstal RM, Bailey TS, Rodbard D, et al. Comparison of insulin glargine 300 units/ml and 100 units/ml in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 2017;40:554-60
   PubMed Web of Science ®Google Scholar
• Heise T, Norskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab 2017;19:1032-9
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42
   PubMed Web of Science ®Google Scholar
• Zinman B, DeVries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol 2013;1:123-31
   PubMed Web of Science ®Google Scholar
• Bode BW, Chaykin LB, Sussman AM, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (BEGIN: COMPARE). Endocr Pract 2014;20:785-91
   PubMed Web of Science ®Google Scholar
• Distiller LA, Nortje H, Wellmann H, et al. A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of U-500 regular insulin plus metformin. Endocr Pract 2014;20:1143-50
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-62
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-43
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-94
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38:2217-25
   PubMed Web of Science ®Google Scholar
• Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract 2015;21:782-93. Erratum in: Endocr Pract 2016;22:905
   PubMed Web of Science ®Google Scholar
• Mari A, Rosenstock J, Ma X, et al. Optimized human regular U-500 insulin treatment improves beta-cell function in severely insulin-resistant patients with long-standing type 2 diabetes and high insulin requirements. Endocr Pract 2015;21:1344-52. Erratum in: Endocr Pract 2016;22:646
   PubMed Web of Science ®Google Scholar
• Riddle MC, Yki-Järvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 2015;17:835-42
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859-67
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus insulin glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab 2015;17:1142-9
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab 2016;18:375-83
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther 2016;18:252-7
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab 2016;18:366-74
   PubMed Web of Science ®Google Scholar
• Wysham C, Hood RC, Warren ML, et al. Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes. Endocr Pract 2016;22:653-65
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract 2016;122:133-40
   PubMed Web of Science ®Google Scholar
• Yale J-F, Harris SB, Berard L, et al. Safety and efficacy of a pragmatic self-titration 1 unit/day (INSIGHT) algorithm for insulin glargine 300 U/ml (GLA-300). Diabetologia 2016;59(Suppl1):S440, 911
   Web of Science ®Google Scholar
• Warren M, Chaykin L, Jabbour S, et al. Insulin degludec 200 units/ml is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 units/ml in patients with type 2 diabetes requiring high-dose insulin. Clin Diabetes 2017;35:90-5
   PubMedGoogle Scholar
• Owens DR. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opin Drug Metab Toxicol 2016;12:977-87
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. January, 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf [Last accessed 9 June 2016]
   Google Scholar
• US Food and Drug Administration. U.S. Department of Health and Human Services. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs – general considerations. March, 2014. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf [Last accessed 10 June 2016]
   Google Scholar
• Simpson D, McCormack PL, Keating GM, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007;67:407-34
   PubMed Web of Science ®Google Scholar
• Esposito K, Capuano A, Giugliano D. Humalog (lispro) for type 2 diabetes. Expert Opin Biol Ther 2012;12:1541-50
   PubMed Web of Science ®Google Scholar
• Segal AR, Brunner JE, Burch FT, et al. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010;67:1526-35
   PubMed Web of Science ®Google Scholar
• Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol 2012;6:412-20
   PubMedGoogle Scholar
• Eby EL, Zagar AJ, Wang P, et al. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes. Endocr Pract 2014;20:663-70
   PubMed Web of Science ®Google Scholar
• Johnson JL, Downes JM, Obi CK, et al. Novel concentrated insulin delivery devices: developments for safe and simple dose conversions. J Diabetes Sci Technol 2017;11:618-22
   PubMedGoogle Scholar
• Reid TS, Schafer F, Brusko C. Higher concentration insulins: an overview of clinical considerations. Postgrad Med 2017;129:554-62
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
   PubMed Web of Science ®Google Scholar
• Heinemann L. Time–Action Profiles of Insulin Preparations. Mainz, Germany: Kirchheim & Co GmbH, 2004
   Google Scholar
• Becker RH. Pharmacodynamic evaluation: diabetes methodologies. In: Vogel HG, Maas J, Gebauer A, editors. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Berlin Heidelberg: Springer-Verlag, 2011:457-81
   Google Scholar
• Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract 2014;20:75-83
   PubMed Web of Science ®Google Scholar
• Binder C. Absorption of injected insulin. Acta Pharmacol Toxicol 1969;27(Suppl2):1-87
   Google Scholar
• Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366-76
   PubMed Web of Science ®Google Scholar
• Clinical Trials at NovoNordisk. Bioequivalence of two insulin aspart formulations (100 U/mL versus 200 U/mL). Available at: http://www.novonordisk-trials.com/WebSite/search/TrialDetail.aspx?Command=GetTrialDetail&TrialId=PDS290-1750&Index=145 [Last accessed 8 June 2016]
   Google Scholar
• Clinical Trials at NovoNordisk. Bioequivalence of two NovoLog formulations in subjects with type 1 diabetes. Available at: http://www.novonordisk-trials.com/WebSite/search/TrialDetail.aspx?Command=GetTrialDetail&TrialId=ANA-3501&Index=17 [Last accessed 8 June 2016]
   Google Scholar
• Clinical Trials at NovoNordisk. Comparison of two insulin aspart formulations in healthy volunteers. Available at: http://www.novonordisk-trials.com/WebSite/search/TrialDetail.aspx?Command=GetTrialDetail&TrialId=NN248-1494&Index=213 [Last accessed 8 June 2016]
   Google Scholar
• Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012;6:728-42
   PubMedGoogle Scholar
• Gough SC, Harris S, Woo V, et al. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15:301-9
   PubMed Web of Science ®Google Scholar
• Vora J, Cariou B, Evans M, et al. Clinical use of insulin degludec. Diabetes Res Clin Pract 2015;109:19-31
   PubMed Web of Science ®Google Scholar
• Kabul S, Hood RC, Duan R, et al. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Health Qual Life Outcomes 2016;14:139
   PubMed Web of Science ®Google Scholar
• Rubin DJ, Rybin D, Doros G, et al. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 2011;34:1723-8
   PubMed Web of Science ®Google Scholar
• U100 insulin: a new era in diabetes mellitus therapy (special report). Diabetes 1972;21:832
   Web of Science ®Google Scholar
• Humulin R U-500 [package insert]. Indianapolis, IN, USA: Eli Lilly and Company, 2016
   Google Scholar
• Bzowyckyj AS. Embracing the insulin revolution in the ambulatory care setting. Diabetes Spectr 2016;29:140-5
   PubMedGoogle Scholar
• QuintilesIMS LifeLink. February 2016 to January 2017
   Google Scholar
• Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-97
   PubMedGoogle Scholar
• Schaepelynck P, Riveline JP, Renard E, et al. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Ther 2014;16:582-9
   PubMed Web of Science ®Google Scholar
• Phillips NF, Hua QX, Wan ZL, et al. Ultra-concentrated insulins: design and pre-clinical validation of a rapid-acting U-500+ insulin analog formulation. Diabetes 2012;61(Suppl1):LB-51
   Google Scholar
• US National Library of Medicine. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/ [Last accessed 29 September 2016]
   Google Scholar
• European Medicines Agency. Available at: http://www.ema.europa.eu/ema/ [Last accessed 29 September 2016]
   Google Scholar
• Lantus [package insert]. Bridgewater, NJ, USA: Sanofi-Aventis, 2015
   Google Scholar
• Institute for Safe Medication Practices. Misuse of new insulin strengths. Acute Care 2016;21(12):3-4
   Google Scholar
• European Medicines Agency. Guidance on prevention of medication errors with high-strength insulin. 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Recommendation_on_medication_errors/2015/11/WC500197133.pdf [Last accessed 12 November 2016]
   Google Scholar